In today’s episode of PsycBiz, James —the Psychedelic Investor— sits down with Mark Haden, VP of Business Development for Clearmind Medicine (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0).
Clearmind is a next-gen psychedelics company working on treating addiction. Their main candidate is a next-gen psychedelic called MEAI. Currently, MEAI is being researched as a treatment for various forms of addiction, including Alcohol Use Disorder.
Though Clearmind’s MEAI is in its early stages, both pre-clinical results and anecdotal evidence suggests that it will be effective. The company plans to launch a phase 1 safety trial by the end of this year.
Mark Haden is a wonderful presenter, and I hope you enjoy this episode.
Before working with Clearmind, he worked at MAPS.
#Alcoholism #Addiction #Psychedelics
Have you heard about our new community?
We’re excited to announce Bonfire -
a personal growth community for people who are interested in psychedelics.
Join us for our launch event on July 18th, where we’ll share about the work we’ll be doing together to actualize our personal missions, grow, and heal together.
Psychedelic Spotlight is your reliable source for the latest stories in the emerging psychedelics industry, covering breakthrough discoveries, investor news and cultural reform.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.